Risk markers of arterial aging in older adults — Paris Prospective III-2
Risk Markers of Arterial Aging and Subsequent Risk of Cardiovascular Diseases and Beyond. The Paris Prospective Study III-2
This follow-up will re-examine people who took part in the original Paris cohort to measure changes in arterial stiffness and baroreflex over about 12–16 years and see if those changes predict later heart and blood vessel disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7500 (estimated) |
| Ages | 60 Years to 95 Years |
| Sex | All |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 1 site (Paris) |
| Trial ID | NCT06079424 on ClinicalTrials.gov |
What this trial studies
The project re-invites survivors and original participants from the Paris Prospective Study III for a second physical exam roughly 12–16 years after baseline to describe the dynamics of vascular aging and baroreflex sensitivity. Participants will undergo high-precision carotid echo-tracking and a new ultrafast radial artery echo to measure arterial aging parameters in large and medium-sized arteries. Blood samples may be collected and biobanked depending on funding. The study will link changes in these vascular measures to subsequent cardiovascular disease events in the well-characterized cohort of 10,157 adults who were 50–75 years old at baseline.
Who should consider this trial
Good fit: Ideal candidates are original PPS3 participants who are alive, able to attend the Paris follow-up visit, and who sign the informed consent for PPS3-2.
Not a fit: People who are institutionalized or under legal guardianship or cannot attend the follow-up visit are excluded and would not be able to participate or benefit from this protocol.
Why it matters
Potential benefit: If successful, the study could identify early vascular aging markers that help predict and prevent future cardiovascular disease.
How similar studies have performed: Previous cohort research has linked arterial stiffness to cardiovascular risk, but long-term repeated measures using high-precision carotid echo-tracking and ultrafast radial echo over a 12–16 year interval are relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being enrolled in PPS3 and having signed an informed consent for PPS3-2 Exclusion Criteria: * Institutionalized participants * Participants under guardianship * Participants under judicial safeguard measure
Where this trial is running
Paris
- Centre d'Investigation Précliniques — Paris, France (Recruiting)
Study contacts
- Principal investigator: Jean-Philippe Empana, MD, PhD — Institut National de la Santé Et de la Recherche Médicale, France
- Study coordinator: Jean-Philippe Empana, MD, PhD
- Email: jean-philippe.empana@inserm.fr
- Phone: 33153988020
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.